1-20 of 809
cd38
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preanalytic depletion of medicinal anti-CD38 antibody from patient plasma for immunohematology testing

Elisabeth Ehrend, Patricia Manns, Sabine Harenkamp, Erhard Seifried, Christof Geisen, Halvard Bonig
Journal: Blood
Blood (2021) 138 (9): 814–817.
https://doi.org/10.1182/blood.2021011396
Published: 2021
Includes: Supplemental data
Journal Articles

T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis

Vandana Chaturvedi, Rebecca A. Marsh, Adi Zoref-Lorenz, Erika Owsley, Vijaya Chaturvedi, Trung C. Nguyen, Jordana R. Goldman, Michael M. Henry, Jay N. Greenberg, Stephan Ladisch, Michelle L. Hermiston, Michael Jeng, Ahmed Naqvi, Carl E. Allen, Hector R. Wong, Michael B. Jordan
Journal: Blood
Blood (2021) 137 (17): 2337–2346.
https://doi.org/10.1182/blood.2020009499
Published: 2021
Includes: Supplemental data
Journal Articles

A Bispecific CAR-T Cell Therapy Targeting Bcma and CD38 for Relapsed/Refractory Multiple Myeloma: Updated Results from a Phase 1 Dose-Climbing Trial

Chenggong Li, Heng Mei, Yu Hu, MD PhD, Tao Guo, MD PhD, Lin Liu, MD PhD, Huiwen Jiang, Lu Tang, Yaohui Wu, MD PhD, Lisha Ai, MD PhD, Jun Deng, MD PhD, Dan Jin
Journal: Blood
Blood (2019) 134 (Supplement_1): 930.
https://doi.org/10.1182/blood-2019-130340
Published: 2019
Journal Articles

CD38 Knockout Primary NK Cells to Prevent "Fratricide" and Boost Daratumumab Activity

Yuya Nagai, MD, Meisam Naeimi Kararoudi, PhD DVM, Ezgi Elmas, MS, Marcelo Pereira, Syed Abbas Ali, MD, Philip Hollingsworth Imus, MD, Dean Anthony Lee, MD PhD, Gabriel Ghiaur, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 870.
https://doi.org/10.1182/blood-2019-129456
Published: 2019
Journal Articles

Daratumumab Inhibits AML Metabolic Capacity and Tumor Growth through Inhibition of CD38 Mediated Mitochondrial Transfer from Bone Marrow Stromal Cells to Blasts in the Leukemic Microenvironment

Jayna J Mistry, BSc, Charlotte Hellmich, MBBChir, Jamie A Moore, BSc, MSc, Christopher R Marlein, PhD, Genevra Pillinger, MB BS, Angela Collins, MBBS, Kristian M Bowles, MBBS, PhD, Stuart A Rushworth, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1385.
https://doi.org/10.1182/blood-2019-128592
Published: 2019
Journal Articles

Stringent Small Molecule Dose Requirements for the Optimal Expansion of Hematopoietic Stem Cells Revealed By Predictive Analytics and Xenotransplants

Javed K Manesia, PhD, Sakhar Almoflehi, Roya Pasha, Suria Jahan, MSc, John Blake, PhD, Julie Audet, PhD, Nicolas Pineault, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1185.
https://doi.org/10.1182/blood-2019-128692
Published: 2019
Journal Articles

Deficit of Circulating CD19 + CD24 hi CD38 hi Regulatory B Cells in Severe Aplastic Anemia

Yoshitaka Zaimoku, MD PhD, Bhavisha A Patel, MD, Sachiko Kajigaya, PhD, Xingmin Feng, PhD, Lemlem Alemu, BS, Diego Quinones Raffo, MSc, Emma M. Groarke, MD, Neal S. Young, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1219.
https://doi.org/10.1182/blood-2019-127053
Published: 2019
Journal Articles

Identification of an Expanded Immature Cell Population in Human Bone Marrow during Erythroid Responses to ESA Treatment

Isabel Juliana F Hofman, PhD, Teresa Mortera-Blanco, PhD, Sigita Venckute Larsson, Sten Eirik Waelgaard Jacobsen, MD PhD, Petter S Woll, PhD, Marios Dimitriou, PhD, Eva Hellstrom Lindberg, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2993.
https://doi.org/10.1182/blood-2019-130065
Published: 2019
Journal Articles

Molecular Genetics and Prognosis in Younger Patients with Chronic Lymphocytic Leukemia (CLL)

Daniel Helbig, MD, Ghaith Abu Zeinah, MD, Erica B Bhavsar, BS, Richard R. Furman, MD, John N. Allan, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3025.
https://doi.org/10.1182/blood-2019-125426
Published: 2019
Journal Articles

The Locommotion Study (MMY4001): A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients with Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMiD, and CD38 Monoclonal Antibody Treatment and Documented Disease Progression

Michel Delforge, MD PhD, Philippe Moreau, MD, Maria-Victoria Mateos, Valerio De Stefano, MD, Katja Weisel, Jesús San-Miguel, Hermann Einsele, MD, Thierry Facon, MD, Mario Boccadoro, Hartmut Goldschmidt, Michele Cavo, Laura Rosinol, MD PhD, Martin F. Kaiser, Francesca Gay, MD, Christof Scheid, MD, Annemiek Broyl, MD PhD, Niels W. C. J. Van De Donk, MD PhD, Paula Rodriguez, MD, Anna Potamianou, Caline Sakabedoyan, Vadim Strulev, Tonia Nesheiwat, Paul Bergmans, Syed Rizvi, MD, Arkadiusz Pilatowicz, Pieter Sonneveld
Journal: Blood
Blood (2019) 134 (Supplement_1): 5549.
https://doi.org/10.1182/blood-2019-122939
Published: 2019
Journal Articles

Preclinical Development of an Anti-CD38 Antibody-Drug Conjugate for Treatment of Hematological Malignancies

Lingna Li, PhD, Wenyong Tong, PhD, Megan Lau, BS, Katherine Fells, PhD, Tong Zhu, PhD, Yingqing Sun, PhD, Ernest Kovacs, PhD, Alisher Khasanov, PhD, Zheng Yan, PhD, Dalun Deng, PhD, Ken Takeshita, MD, Gunnar F. Kaufmann, PhD, Henry Ji, PhD, Hui Li, PhD, Hong Zhang, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5621.
https://doi.org/10.1182/blood-2019-132062
Published: 2019
Journal Articles

Establishment and Characterization of a Myeloma Cell Line- Aku-MY01

Sheerien Kareem Rajput, BSc,MSc, El-Nasir M A Lalani, BSc MBChB FRCPath PhDFHEA
Journal: Blood
Blood (2019) 134 (Supplement_1): 5535.
https://doi.org/10.1182/blood-2019-132238
Published: 2019
Journal Articles

Targeting CD38 high Acute Myeloid Leukaemia with "Affinity Optimized" Chimeric Antigen Receptor and Membrane Bound TRAIL Expressing Natural Killer Cells

Emma Nolan, BSc, Arwen Stikvoort, PhD, Mark Gurney, MD, Nutsa Burduli, BSc, Lucy Kirkham-McCarthy, MSc, John Daly, MSc, Niels W. C. J. Van De Donk, Tuna Mutis, MD PhD, Subhashis Sarkar, PhD, Michael E O'Dwyer, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5536.
https://doi.org/10.1182/blood-2019-128605
Published: 2019
Journal Articles

Predicting the Long-Term Efficacy of Ifnα in JAK2 V617F and Calr -Mutated MPN Patients

Amandine Tisserand, Robert Noble, PhD, Matthieu Mosca, PhD, Christophe Marzac, MD, Gaelle Vertenoeil, MD, Hugo Campario, PharmD, Mira El-Khoury, PhD, Caroline Marty, PhD, Philippe Rameau, Nicole Casadevall, MD, Eric Solary, MD PhD, Florence Pasquier, MD PhD, Hana Raslova, PhD, Bruno Cassinat, PharmD, PhD, Stefan N Constantinescu, MD PhD, Jean-Jacques Kiladjian, MD PhD, Francois Girodon, MD PhD, Michael Hochberg, PhD, Villeval Jean-Luc, PhD, William Vainchenker, MD PhD, Isabelle Plo
Journal: Blood
Blood (2019) 134 (Supplement_1): 4196.
https://doi.org/10.1182/blood-2019-127903
Published: 2019
Journal Articles

A Novel Class of Bifunctional Immunotherapeutic That Exploits a Universal Antibody Binding Terminus (uABT) to Recruit Endogenous Antibodies to Cell Expressing CD38 Demonstrate In Vivo efficacy in Three Distinct Animal Models

Anna Bunin, PhD, Katy McGrath, BS, Ann Marie Rossi, MS, Matthew Welsch, PhD, Christian Vidal, PhD, David Trinh, BA, David Spiegel, MD, PhD, Luca Rastelli, PhD, Enrique Alvarez, DVM
Journal: Blood
Blood (2019) 134 (Supplement_1): 1820.
https://doi.org/10.1182/blood-2019-130838
Published: 2019
Journal Articles

Dreamm-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-directed Immuno-conjugate) in Combination with Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM)

Paul G. Richardson, MD, Swethajit Biswas, Beata Holkova, Nicola Jackson, Thelma Netherway, Weichao Bao, Geraldine Ferron-Brady, Anne Yeakey, Chris Shelton, Rocio Montes De Oca, PhD, Chris Ahlers, Sonia Franco, Marc Ballas, Elaine Paul, Katarina Luptakova, Ira Gupta, Joanna Opalinska
Journal: Blood
Blood (2019) 134 (Supplement_1): 1857.
https://doi.org/10.1182/blood-2019-129879
Published: 2019
Journal Articles

MRD Detection in Myeloma Cells: Comparison between Inexpensive 1-Tube 10 Color Multiparameter Flow Cytometry and Euroflow Multiparameter Flow Cytometry

Kiyoshi Okazuka, MD, Tadao Ishida, MD PhD, Jun Sakamoto, Nobuhiro Tsukada, MD PhD, Kenshi Suzuki, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1832.
https://doi.org/10.1182/blood-2019-123900
Published: 2019
Journal Articles

Targeting Nicotinamide Adenine Dinucleotide (NAD) Glycohydrase Activity of CD38 Exerts Anti-Myeloma Effect Accompanying Intracellular NAD Elevation

Saki Kushima, Takayuki Sasano, Masao Matsuoka, MD PhD, Hiroyuki Hata, MD PhD, Yawara Kawano, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1810.
https://doi.org/10.1182/blood-2019-123624
Published: 2019
Journal Articles

A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug (IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or Naïve to Daratumumab (dara)

Shaji K. Kumar, MD, Robert F. Cornell, MD MS, Ola Landgren, MD PhD, Sikander Ailawadhi, MD, Jack P Higgins, PhD, Erin K Willert, Roger Waltzman, MD MBA, Jianchang Lin, PhD, Yuhong Zhang, Anya R Lublinsky, Ajeeta B Dash, PhD, Michael Hanley, Divya Manoharan, Morgan Leichter, Sean Ottinger, Richard J Labotka, John Newcomb, Alexander Vorog, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1867.
https://doi.org/10.1182/blood-2019-125629
Published: 2019
Journal Articles

Ex Vivo Activity of Immunotherapeutic Approaches Targeting CD38 Against Daratumumab-Resistant Multiple Myeloma Patient Samples

Maria Karvouni, MSc, PharmD, Heyue Zhou, Arnika Kathleen Wagner, PhD, Qiangzhong Ma, Alamdar H. Baloch, PhD, Tong Zhu, Hong Zhang, Mari Gilljam, Andreas Lundqvist, PhD, Gunnar F. Kaufmann, PhD, Evren Alici, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1848.
https://doi.org/10.1182/blood-2019-127893
Published: 2019